Nixon Peabody LLP

  • People
  • Capabilities
  • Insights
  • About

Trending Topics

    • People
    • Capabilities
    • Insights
    • About
    • Locations
    • Events
    • Careers
    • Alumni

    Practices

    View All

    • Affordable Housing
    • Community Development Finance
    • Corporate & Finance
    • Cybersecurity & Privacy
    • Environmental
    • Franchising & Distribution
    • Government Investigations & White Collar Defense
    • Healthcare
    • Intellectual Property
    • International Services
    • Labor & Employment
    • Litigation
    • Private Wealth & Advisory
    • Project Finance
    • Public Finance
    • Real Estate
    • Regulatory & Government Relations

    Industries

    View All

    • Cannabis
    • Consumer
    • Energy
    • Entertainment
    • Financial Services
    • Healthcare
    • Higher Education
    • Infrastructure
    • Manufacturing
    • Non Profit
    • Real Estate
    • Technology

    Value-Added Services

    View All

    • Alternative Fee Arrangements

      Developing innovative pricing structures and alternative fee agreement models that deliver additional value for our clients.

    • Continuing Education

      Advancing professional knowledge and offering credits for attorneys, staff and other professionals.

    • Crisis Advisory

      Helping clients respond correctly when a crisis occurs.

    • DEI Strategic Services

      Providing our clients with legal, strategic, and practical advice to make transformational changes in their organizations.

    • eDiscovery

      Leveraging law and technology to deliver sound solutions.

    • Global Services

      Delivering seamless service through partnerships across the globe.

    • Innovation

      Leveraging leading-edge technology to guide change and create seamless, collaborative experiences for clients and attorneys.

    • IPED

      Industry-leading conferences focused on affordable housing, tax credits, and more.

    • Legal Project Management

      Providing actionable information to support strategic decision-making.

    • Legally Green

      Teaming with clients to advance sustainable projects, mitigate the effects of climate change, and protect our planet.

    • Nixon Peabody Trust Company

      Offering a range of investment management and fiduciary services.

    • NP Capital Connector

      Bringing together companies and investors for tomorrow’s new deals.

    • NP Second Opinion

      Offering fresh insights on cases that are delayed, over budget, or off-target from the desired resolution.

    • NP Trial

      Courtroom-ready lawyers who can resolve disputes early on clients’ terms or prevail at trial before a judge or jury.

    • Social Impact

      Creating positive impact in our communities through increasing equity, access, and opportunity.

    1. Home
    2. Insights
    3. Alerts
    4. Antibody patenting in light of Amgen v. SanofiAlerts

    Alert / Intellectual Property Alert

    Antibody patenting in light of Amgen v. Sanofi

    Jan 25, 2019

    Share

    By Linda Huber and Suwei Samantha Zhu, Ph.D.

    This alert provides helpful information about antibody-related patent protection in light of Amgen and the USPTO memorandum.

    DOWNLOADS

    Knowledge of a newly characterized antigen for patenting a genus of its cognate antibodies is not quite enough, according to Amgen Inc. v. Sanofi (Fed. Cir. 2017). The “newly characterized antigen” test is opined to be inappropriate in determining whether a patent application for an antibody satisfies the written description requirement. Although several pharmaceutical companies concurred with Amgen and voiced strong concerns about the “narrow and inflexible rule” created by the Federal Circuit, Amgen’s petition for certiorari to the Supreme Court to take up the issue of written description was denied in early January, 2019.

    The United States Patent and Trademark Office (USPTO) issued a memorandum adopting Amgen as the law on written description as it applies to antibodies and pointed out that 35 U.S.C. § 112(a) requires adequate written description of the antibody itself.

    Even in light of Amgen and the USPTO memorandum, successful prosecution of patent applications directed to antibodies and therapeutic methods of using antibodies can still be achieved. Applicants are reminded that:

    • Making a biological deposit of hybridomas at any time before allowance remains a viable option in many instances for a U.S. patent application to satisfy the written description requirement. For certain foreign jurisdictions, such as Europe, applicants should ensure that biological samples are deposited on or before the effective filing date of the application (i.e., before the filing date of the priority application, if one is filed), for the invention to be considered sufficiently disclosed as of the effective filing date. Under the European Patent Convention, a biological deposit made between a priority application and a subsequent European application is too late for the invention to be considered sufficiently disclosed in the priority application, resulting in a loss of the priority date.
    • Amino acid sequences of the complementarity-determining regions (CDRs), if known, should be included.
    • Disclosures relating to substitutions, additions or deletions of amino acids in the CDRs along with functional features such as binding affinity and therapeutic efficacy may help broaden the scope of protection.
    • To protect a genus of antibodies, disclosure of a representative number of species and/or common structural features among the members of the genus should be made.

    The particular nuances of each invention need to be considered on a case-by-case basis against the evolving laws in each jurisdiction of interest when formulating and revisiting one’s strategy for antibody-related patent protection.

    Practices

    Life SciencesIntellectual Property

    Insights And Happenings

    • Alert

      Gut check: microbiome patent update

      Feb 12, 2020
    • Press Release

      Nixon Peabody client recognized as one of the worlds top 100 innovators

      Oct 18, 2019
    • Article

      Patent Plantings

      Sep 9, 2019

    Subscribe to stay informed of the latest legal news, alerts, and business trends.Subscribe

    • People
    • Capabilities
    • Insights
    • About
    • Locations
    • Events
    • Careers
    • Alumni
    • © 2023 Nixon Peabody. All rights reserved
    • Privacy Policy
    • Terms of Use
    • Statement of Client Rights
    • Supplier Diversity Program
    • Nixon Peabody International LLC
    • PAL